Levaquin Approved to Treat or Prevent Plague

Deadly disease rare in the United States

MONDAY, April 30 (HealthDay News) -- Approval of the antibiotic Levaquin (levofloxacin) has been expanded by the U.S. Food and Drug Administration to include plague, a rare but deadly bacterial infection.

The disease is extremely rare in the United States, and only about 1,000 to 2,000 cases occur each year across the globe, the agency said in a news release. The three most common forms of plague include bubonic (affecting the lymph nodes), pneumonic (lungs), and septicemic (blood stream).

Animals are most frequently infected, although plague can be spread to people by fleas, contact with infected animals or other people, or by exposure in the laboratory. The bacterium that causes plague, Yersinia pestis, is considered a potential bioterrorism agent, the FDA said.

Levaquin was tested under the agency's Animal Efficacy Rule, which allows findings from carefully controlled tests in animals to be applied to people. It would not be ethical or feasible to conduct clinical testing of the drug for this purpose in people, the FDA said.

Known side effects of Levaquin include nausea, headache, diarrhea, insomnia, constipation, and dizziness. More serious but rare adverse reactions could include tendinitis and tendon rupture, allergic reactions, liver damage, blood and nervous system problems, and abnormal heart rhythm, the agency said.

Levaquin is produced by Raritan, N.J.-based Janssen Pharmaceuticals, a unit of Johnson & Johnson.

More information

Medline Plus has more about Levaquin.

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Blunt Chest Trauma
Journal of Trauma Nursing, November/December 2014
Expires: 12/31/2016 CE:2 $21.95


The School Age Child with Congenital Heart Disease
MCN, The American Journal of Maternal/Child Nursing, January/February 2015
Expires: 2/28/2017 CE:2.5 $24.95


Understanding multiple myeloma
Nursing Made Incredibly Easy!, January/February 2015
Expires: 2/28/2017 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles

Comprehensive Care: Looking Beyond the Presenting Problem
Journal of Christian Nursing, January/March 2015
Free access will expire on March 2, 2015.


Pain and Alzheimer dementia: A largely unrecognized problem
Nursing Made Incredibly Easy!, January/February 2015
Free access will expire on February 16, 2015.


Glycemic control in hospitalized patients
Nursing2015 Critical Care, January 2015
Free access will expire on February 16, 2015.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events